Podcast
Kirk Shepard
Reinvent innovation and become an R&D front-runner by 2030
Summary
R&D’s risk profile is becoming unsustainable. With a history of declining productivity, the onset of personalized medicine and new entrants causing havoc, Life Sciences executives should fundamentally revisit their approach to R&D. By 2030, these companies will be adopting methods that focus on outsourcing, resource sharing and advanced technologies. Leading companies need to become familiar with these trends now, so they can be ready for the future.
Related Topics
You May Also Like
Kirk Shepard
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Guillaume Beinse, MD, Virgile Tellier, Valentin Charvet, MSc, Eric Deutsch, MD, PhD, Isabelle Borget, PharmD, PhD, Christophe Massard, MD, PhD., Antoine Hollebecque, MD, PhD, and Loic Verlingue, MD
Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2
Article
Massimo Di Maio, Francesco Perrone, Pierfranco Conte
Real-World Evidence in Oncology: Opportunities and Limitations
Article
Thakur, Sayanta & Lahiry, Sandeep
Accelerated drug approvals in oncology: Pros and cons
Podcast
The Oncology Nursing Podcast